Voriconazole For Chronic Bronchopulmonary Aspergillosis
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy of voriconazole (VFend(R)) as first line treatment for proven
chronic bronchopulmonary aspergillosis, in minimally immunocompromised or
non-immunocompromised patients after 6 months of treatment i.e. chronic necrotizing pulmonary